세계의 만성 골수성 백혈병 치료 시장 보고서(2025년)

Chronic myeloid leukemia (CML) treatment involves addressing the uncontrolled growth of abnormal white blood cells in the blood and bone marrow. These cells, known as myeloid cells, play a crucial role in fighting infections and maintaining the immune system.

The primary types of CML treatment include targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. Targeted therapy is a cancer treatment approach that employs drugs to specifically target genes and proteins supporting the growth and survival of cancer cells. In the context of CML treatment, targeted therapy aims to identify and eliminate specific cancer cell types while minimizing damage to healthy cells. Various drugs, including tyrosine kinase inhibitors, antimetabolites, and others, are utilized in hospitals, clinics, and other healthcare settings for CML treatment. These medications are accessible through hospital pharmacies, retail pharmacies, and online pharmacy platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chronic myeloid leukemia (CML) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia (CML) treatment market statistics, including the chronic myeloid leukemia (CML) treatment industry's global market size, regional shares, competitors with a chronic myeloid leukemia (CML) treatment market share, detailed chronic myeloid leukemia (CML) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (CML) treatment industry. This chronic myeloid leukemia (CML) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increased awareness and early detection, clinical trial outcomes, targeted therapies development, patient advocacy and support groups, healthcare infrastructure development.

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $11.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to personalized medicine approaches, combination therapies, increasing patient access to novel therapies, government policies supporting orphan drugs, rising healthcare expenditure. Major trends in the forecast period include global collaboration in research, telemedicine and remote monitoring, development of next-generation tkis, treatment optimization strategies.

The forecast of 7.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. oncology by increasing the cost of tyrosine kinase inhibitors and BCR-ABL polymerase chain reaction(PCR) test kits sourced from Switzerland and the Netherlands, thereby compromising molecular remission rates and elevating cancer treatment expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The projected rise in the incidence and prevalence of chronic myeloid leukemia (CML) is anticipated to be a significant driver of growth in the chronic myeloid leukemia (CML) treatment market. This type of leukemia, also known as chronic myelogenous leukemia, profoundly impacts the bone marrow and blood by causing an excessive production of immature myeloid cells. Treatment for chronic myeloid leukemia is crucial in slowing down its progression and preventing its advancement to more severe stages. For instance, based on data from the American Society of Clinical Oncology in March 2023, the United States expects a substantial number of individuals, around 35,730, to be diagnosed with multiple myeloma. Furthermore, approximately 12,590 deaths due to this disease are anticipated in 2023. These statistics underscore the pressing need for effective treatments, thereby driving the growth of the chronic myeloid leukemia (CML) treatment market.

The rise of personalized medicine has significantly impacted the chronic myeloid leukemia (CML) treatment market. This approach helps physicians create individualized treatment plans and make informed decisions based on a patient's genetic profile. In CML, personalized medicine focuses on identifying specific molecular targets, notably the BCR-ABL fusion gene, which enhances understanding of the genetic abnormalities that drive the disease in each patient. This facilitates early intervention and tailored preventive strategies. For example, in February 2023, the Personalized Medicine Coalition (PMC), a US-based non-profit organization, reported that personalized medicines designed for specific patient subpopulations with unique biological characteristics accounted for 34 percent of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2022. Consequently, the advancement of personalized medicine is anticipated to propel the growth of the chronic myeloid leukemia (CML) treatment market.

Product innovation is a significant trend gaining traction in the chronic myeloid leukemia (CML) treatment market. Companies in this sector are embracing new technologies to maintain their competitive edge. For example, in August 2022, Novartis AG, a pharmaceutical company based in Switzerland, announced that the European Commission (EC) approved Scemblix for managing adult patients with chronic myeloid leukemia in the chronic phase (Ph+ CML-CP), which is chromosome-positive. Scemblix is the first treatment in Europe that specifically targets the ABL myristoyl pocket, known as a STAMP inhibitor in scientific literature. This innovative mechanism offers a new treatment option for patients who have developed intolerance or resistance to existing tyrosine kinase inhibitors (TKIs). By rethinking the treatment approach, Scemblix meets the needs of those who struggle with current therapies.

Strategic partnerships and collaborations are key focal points for companies aiming to broaden their product spectrum and geographical footprint. For instance, Xspray Pharma, a Sweden-based biotechnology company, forged a partnership with EVERSANA, a US-based life sciences entity, in February 2023. This collaboration aims to support the US launch and commercialization of Dasynoc (XS004), a promising treatment for chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Though pending FDA approval and contingent upon legal conditions, Dasynoc signifies a novel treatment option anticipated to penetrate the lucrative $3.5 billion Tyrosine Kinase Inhibitors market in the United States. Leveraging EVERSANA's specialized commercialization team entrenched in the oncology market, Xspray aims for a tailored and effective approach to introduce Dasynoc, with a projected launch slated for the latter half of 2023. This strategic move holds the promise of significantly enhancing treatment options for CML and ALL patients within the US market.

In August 2022, the US-based multinational pharmaceutical company Bristol Myers Squibb successfully acquired Turning Point Therapeutics for $4.1 billion. This strategic acquisition provides Bristol Myers Squibb with access to Turning Point Therapeutics' pipeline of experimental drugs, notably repotrectinib, designed to target prevalent mutations associated with oncogenesis. Turning Point Therapeutics, based in the US, specializes in the development of precision medicines for cancer and other diseases, including tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia (CML).

Major companies operating in the chronic myeloid leukemia (CML) treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2024. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic myeloid leukemia (cml) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia (cml) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia (cml) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic myeloid leukemia (cml) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
• 2) By Drug Type: Tyrosine Kinase Inhibitors; Antimetabolites; Other Drug Types
• 3) By Application: Hospitals; Clinic; Other Applications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Other Targeted Agents
• 2) By Chemotherapy: Combination Regimens; Single-Agent Therapies
• 3) By Radiation Therapy: Palliative Radiation; Total Body Irradiation
• 4) By Splenectomy: Laparoscopic Splenectomy; Open Splenectomy
• 5) By Stem Cell Transplant: Allogeneic Stem Cell Transplant; Autologous Stem Cell Transplant
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Amgen Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Eisai Co. Ltd.; Fresenius Kabi AG; Sun Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co. Ltd.; Incyte Corporation; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Amneal Pharmaceuticals LLC; Lupin Limited; Innovent Biologics Inc.; Glenmark Pharmaceuticals Limited; Il-Yang Pharmaceutical Co. Ltd.; Accord Healthcare Inc.; ARIAD Pharmaceuticals Inc.; Orca Bio; Bio-Path Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia (CML) Treatment Market Characteristics

3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chronic Myeloid Leukemia (CML) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Myeloid Leukemia (CML) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate Analysis
• 5.4. Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Myeloid Leukemia (CML) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Myeloid Leukemia (CML) Treatment Total Addressable Market (TAM)

6. Chronic Myeloid Leukemia (CML) Treatment Market Segmentation

• 6.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemotherapy
• Radiation Therapy
• Splenectomy
• Stem Cell Transplant
• 6.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Antimetabolites
• Other Drug Types
• 6.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinic
• Other Applications
• 6.4. Global Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Other Targeted Agents
• 6.6. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Regimens
• Single-Agent Therapies
• 6.7. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Palliative Radiation
• Total Body Irradiation
• 6.8. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Splenectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Laparoscopic Splenectomy
• Open Splenectomy
• 6.9. Global Chronic Myeloid Leukemia (CML) Treatment Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allogeneic Stem Cell Transplant
• Autologous Stem Cell Transplant

7. Chronic Myeloid Leukemia (CML) Treatment Market Regional And Country Analysis

• 7.1. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market

• 8.1. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Myeloid Leukemia (CML) Treatment Market

• 9.1. China Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 9.2. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Myeloid Leukemia (CML) Treatment Market

• 10.1. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Myeloid Leukemia (CML) Treatment Market

• 11.1. Japan Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 11.2. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Myeloid Leukemia (CML) Treatment Market

• 12.1. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market

• 13.1. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Myeloid Leukemia (CML) Treatment Market

• 14.1. South Korea Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 14.2. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market

• 15.1. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 15.2. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Myeloid Leukemia (CML) Treatment Market

• 16.1. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Myeloid Leukemia (CML) Treatment Market

• 17.1. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Myeloid Leukemia (CML) Treatment Market

• 18.1. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Myeloid Leukemia (CML) Treatment Market

• 19.1. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Myeloid Leukemia (CML) Treatment Market

• 20.1. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market

• 21.1. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 21.2. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Myeloid Leukemia (CML) Treatment Market

• 22.1. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Myeloid Leukemia (CML) Treatment Market

• 23.1. North America Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 23.2. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Myeloid Leukemia (CML) Treatment Market

• 24.1. USA Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 24.2. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Myeloid Leukemia (CML) Treatment Market

• 25.1. Canada Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 25.2. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Myeloid Leukemia (CML) Treatment Market

• 26.1. South America Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 26.2. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Myeloid Leukemia (CML) Treatment Market

• 27.1. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Myeloid Leukemia (CML) Treatment Market

• 28.1. Middle East Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 28.2. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Myeloid Leukemia (CML) Treatment Market

• 29.1. Africa Chronic Myeloid Leukemia (CML) Treatment Market Overview
• 29.2. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Myeloid Leukemia (CML) Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chronic Myeloid Leukemia (CML) Treatment Market Competitive Landscape
• 30.2. Chronic Myeloid Leukemia (CML) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Myeloid Leukemia (CML) Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Eisai Co. Ltd.
• 31.9. Fresenius Kabi AG
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Otsuka Pharmaceutical Co. Ltd.
• 31.12. Incyte Corporation
• 31.13. Cipla Limited
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Amneal Pharmaceuticals LLC

32. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market

34. Recent Developments In The Chronic Myeloid Leukemia (CML) Treatment Market

35. Chronic Myeloid Leukemia (CML) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Myeloid Leukemia (CML) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer